Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIGA Technologies Inc. -- Ignore unavailable to you. Want to Upgrade?

To: caly who wrote (18)	4/19/2006 4:16:46 PM
From: caly	Read Replies (1) \| Respond to of 160

rarediseases.about.com Orphan drug status approved for Ceflatonin, Valortim On March 19, 2006, the U.S. Food and Drug Administration (FDA) approved orphan drug status for homoharringtonine (Ceflatonin) for the treatment of chronic myeloid leukemia (CML). ChemGenex Pharmaceuticals states in its press release that Ceflatonin is the first of a new class of novel drugs that induces apoptosis (programmed cell death) and inhibits angiogenesis (new blood vessel formation). Ceflatonin is also being investigated as a treatment for myelodysplastic syndrome and acute myeloid leukemia. Ceflatonin was granted orphan drug status by the European Medicines Agency (EMEA) for treatment of CML in September 2004. On March 6, 2006, the FDA approved orphan drug status for MDX-1303 (Valortim) for the treatment of inhalational anthrax infection. Valortim, made by Medarex, Inc., and PharmAthene, Inc., is a human anti-anthrax antibody for use both prior to the start of symptoms (prophylactically) and after symptoms begin (therapeutically). PharmAthene is a privately-held company developing countermeasures to bioterrorism.